Outset Medical, Inc. develops and commercializes dialysis technology centered on the Tablo Hemodialysis System, an FDA-cleared platform used across hospital and home care settings. Company news commonly covers Tablo adoption, consumables and service revenue, product gross margin, cash use, and financial guidance tied to the company’s medical technology business.
Recurring updates also include FDA matters for the Tablo platform, including 510(k) clearance for a next-generation system with cybersecurity, reliability, and connectivity enhancements. Governance and compensation announcements include board changes, executive appointments, and inducement equity grants under Nasdaq rules.
Outset Medical, Inc. (NASDAQ: OM) has released five new abstracts at the National Kidney Foundation Spring Clinical Meetings highlighting innovations in home hemodialysis (HHD) and gender biases in nephrology. The studies demonstrate clinical and financial benefits of HHD, particularly in Hawaii, where Tablo was implemented effectively under challenging conditions. Key findings include a potential savings of $4.2M for Medicare Advantage plans through HHD expansion and estimated savings of $10.7M for providers using risk-based contracts. The research aims to enhance patient choice and access to dialysis options, addressing health disparities and gender equity issues in the field.
Outset Medical, Inc. (NASDAQ: OM) announced plans to release its financial results for Q1 2023 on May 3, 2023, after market close. CEO Leslie Trigg and CFO Nabeel Ahmed will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. The company focuses on revolutionizing dialysis with its Tablo® Hemodialysis System, which simplifies operational processes and enhances patient care. The system integrates water purification and dialysate production, serving as a mobile dialysis clinic. Interested parties can register online for the call and access a live or archived webcast on the Outset Investors page.
Outset Medical, Inc. (Nasdaq: OM), a leader in medical technology, announces participation in a fireside chat at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023, at 9:50 a.m. PT / 12:50 p.m. ET. The event will be available via live and archived webcast on the Outset website.
Outset is known for its innovative Tablo Hemodialysis System, which simplifies dialysis by allowing for its use in various settings, from hospitals to homes. This FDA-cleared technology enhances patient care and operational efficiency, integrating water purification and on-demand dialysate production.
Outset Medical, Inc. (NASDAQ: OM) reported its financial results for Q4 and full year 2022. Q4 revenue was $32.0 million, up 14.0% year-over-year, and full-year revenue reached $115.4 million, marking a 12.4% increase. Gross margin for Q4 was 16.5%, improving significantly from 11.8% in Q4 2021, while full-year gross margin stood at 15.5%. The company increased its Tablo systems installation base by 54% year-over-year. Operating expenses rose to $45.1 million, with a net loss of $41.4 million for Q4. For 2023, Outset maintains revenue guidance of $140 to $150 million, projecting growth of approximately 22% to 30% over 2022.
Outset Medical, Inc. (NASDAQ: OM) will release its financial results for Q4 and full year 2022 on February 13, 2023, post-market. A conference call hosted by CEO Leslie Trigg and CFO Nabeel Ahmed will take place at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the outcomes. Outset's innovative Tablo® Hemodialysis System aims to transform dialysis by simplifying operations and making care accessible in various settings. The system integrates water purification and on-demand dialysate production, enhancing the dialysis experience for patients.
Outset Medical, Inc. (NASDAQ: OM) announced its expected fourth quarter and fiscal year 2022 revenues, projecting approximately $31.5 million for Q4, a 13% increase from Q3, and $115 million for the year, up 12% year-over-year. The installed base of its Tablo® Hemodialysis Systems surged 54% to around 4,000 units. For 2023, Outset anticipates revenues of $140 million to $150 million and a gross margin increase to 20%. The company emphasizes its growth in treating patients and expanding its market presence.
Outset Medical, Inc. (Nasdaq: OM) announces its participation in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 11:15 am PT / 2:15 pm ET. The company focuses on innovative dialysis technology, specifically the Tablo Hemodialysis System, designed to reduce costs and complexity in dialysis treatments. The Tablo system, FDA cleared for both hospital and home use, allows healthcare providers to deliver dialysis care more efficiently. A live and archived webcast will be available on Outset's Investors webpage.
Outset Medical, Inc. (Nasdaq: OM) announces participation in a virtual panel at the BofA Securities Home Care Conference on December 6, 2022, at 12:10 PM PT. The discussion will feature CEO Leslie Trigg and CMO Michael Aragon, alongside two home dialysis patients, focusing on home hemodialysis and end-stage renal disease management. A live and archived webcast will be accessible on the Investors section of Outset’s website. Outset's Tablo® Hemodialysis System aims to simplify dialysis and enhance patient care.
Outset Medical, Inc. announced a remarkable 5,000% revenue growth, totaling $103 million from 2018 to 2021, largely attributed to the adoption of its Tablo® Hemodialysis System. The company ranked 33 on the Deloitte Technology Fast 500 list, reflecting its leadership in the medical technology sector. Outset’s technology aims to simplify dialysis for patients and providers, offering a seamless experience from hospitals to home care.
Outset Medical, Inc. (Nasdaq: OM) announced management participation in two investor conferences. The Stifel 2022 Healthcare Conference is set for November 15, 2022, at 5:35am PT. The Jefferies London Healthcare Conference follows on November 17, 2022, at 5:55am PT. Both sessions will be accessible via live and archived webcasts on the Outset website. Outset is known for its innovative Tablo Hemodialysis System, which simplifies dialysis cost and complexity, enhancing patient care from hospitals to home.